Loading stock data…
MSLE
$7.85-0.10 (-1.26%)
Market ClosedLast close May 1
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Satellos Bioscience Inc. in the Healthcare sector is trading at $7.85. The stock is currently 41% below its 52-week high of $13.39, remaining 10.7% above its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why MSLE maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.85
Potential Upside
5%
Whystock Fair Value$8.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$27.67+252.4%
Range$20.00 – $40.00
Fundamentals
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$141.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.59%
Volume
Today's trading volume
24,378
Recent News
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline the first results. All of the major U.S. indices saw wild swings on Thursday, and after opening the day deep in the red, ... Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Satellos Bioscience: Q4 Earnings Snapshot
TORONTO (AP) — Satellos Bioscience Inc. MSLE) on Friday reported a loss of $7.3 million in its fourth quarter. On a per-share basis, the Toronto-based company said it had a loss of 47 cents.
Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference
Satellos Bioscience (MSCL.TO, NASDAQ: MSLE) was at last look up near 10% in US premarket trade Tuesd
Satellos price target raised to $40 from $5 at Oppenheimer
Oppenheimer raised the firm’s price target on Satellos (MSLE) to $40 from $5 and keeps an Outperform rating on the shares. The firm is updating its model for U.S. listing, and adjusting for 1:12 reverse split and its increase in Duchenne muscular dystrophy market penetration. Oppenheimer sees Satellos as an arbitrage opportunity in DMD space, wherein SAT-3247 Phase II randomized data could move Satellos up 300%-500%/-90%. President's Day Sale - 70% OffUnlock hedge fund-level data and powerful in
Satellos Closes US$57.2 Million Public Offering in Canada and the United States
Satellos Bioscience (MSCL.TO, MSLE) was last seen down 2% in after-hours Nasdaq trading after the co